Cargando…
Adherence/Retention Alzheimer's Prevention Initiative Colombia Plan
INTRODUCTION: The Alzheimer's Prevention Initiative Colombia Trial is a collaborative project involving the Neurosciences Group of Antioquia, Genentech/Roche, and the Banner Alzheimer's Institute, studying whether crenezumab can delay or prevent the clinical onset of Alzheimer's disea...
Autores principales: | Rios-Romenets, Silvia, Acosta-Baena, Natalia, Lopez, Liliana, Madrigal-Zapata, Lucia, Street, Helen, Jakimovich, Laura, Langbaum, Jessica B., Cho, William, Reiman, Eric M., Tariot, Pierre N., Lopera, Francisco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6077834/ https://www.ncbi.nlm.nih.gov/pubmed/30090848 http://dx.doi.org/10.1016/j.trci.2018.06.010 |
Ejemplares similares
-
Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal‐Dominant Alzheimer's Disease Colombia Trial
por: Rios‐Romenets, Silvia, et al.
Publicado: (2020) -
Brain imaging biomarkers for the Alzheimer’s Prevention Initiative
por: Chen, Kewei, et al.
Publicado: (2012) -
The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort
por: Tariot, Pierre N., et al.
Publicado: (2018) -
PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer’s disease-causing Presenilin-1 E280A mutation carriers
por: Ghisays, Valentina, et al.
Publicado: (2021) -
Sex Differences in Cognitive Abilities Among Children With the Autosomal Dominant Alzheimer Disease Presenilin 1 E280A Variant From a Colombian Cohort
por: Fox-Fuller, Joshua T., et al.
Publicado: (2021)